Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.

@article{Bai2003RisperidoneFS,
  title={Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.},
  author={Yamei Bai and S Yu and Chao-Cheng Lin},
  journal={The Journal of clinical psychiatry},
  year={2003},
  volume={64 11},
  pages={1342-8}
}
BACKGROUND Risperidone has been reported to alleviate the severity of tardive dyskinesia, but without placebo control, the possibility of spontaneous tardive dyskinesia remission after discontinuing original conventional antipsychotics cannot be excluded. This 12-week randomized, double-blind, placebo-controlled study investigated the effect of risperidone… CONTINUE READING